Is Dexmedetomidine Associated With a Lower Incidence of Postoperative Delirium When Compared to Propofol or Midazolam in Cardiac Surgery Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00417664|
Recruitment Status : Unknown
Verified January 2007 by Stanford University.
Recruitment status was: Active, not recruiting
First Posted : January 4, 2007
Last Update Posted : January 4, 2007
|Condition or disease||Intervention/treatment||Phase|
|Delirium||Drug: dexmedetomidine Drug: midazolam Drug: propofol||Phase 4|
Delirium is the most common psychiatric syndrome found in the general hospital setting. Between 32 - 80% of cardiac surgery patients may experience post-operative delirium. Because failure to recognize delirium leads to increased morbidity and mortality and prolonged hospital stays, there are compelling clinical and financial reasons to improve the identification and treatment of delirium. Dexmedetomidine, a selective alpha2–adrenergic receptor agonist, may be an alternative to current postoperative sedation when it comes to lowering the incidence of delirium.
Comparisons: The use of postoperative (at sternal closure) dexmedetomidine will be compared to current standards of care propofol and midazolam for postoperative sedation.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||ICU Delirium: Can Dexmedetomidine Reduce Its Incidence?|
|Study Start Date :||April 2002|
|Study Completion Date :||December 2003|
- Postoperative Delirium (DSM-IV criteria)
- Length of Stay (hospital and ICU), use of as needed medications
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00417664
|United States, California|
|Stanford University Medical Center|
|Stanford, California, United States, 94305|
|Principal Investigator:||Jose M Maldonado, MD||Stanford University|